Department of Internal Medicine, Universidade Estadual de Campinas, Campinas, SP, Brazil.
Department of Dermatology, Hospital da Pontifícia Universidade Católica de Campinas, Campinas, SP, Brazil.
An Bras Dermatol. 2024 Jan-Feb;99(1):80-89. doi: 10.1016/j.abd.2022.12.007. Epub 2023 Aug 17.
Psoriasis is associated with several comorbidities and its association with thyroid abnormality has been hypothesized.
To assess the prevalence of thyroid abnormality in Brazilian patients with psoriasis and to analyze its association with severity, presence of psoriatic arthritis and immunobiological treatment. Additionally, to compare results with literature as a control.
In this observational study, clinical and laboratory data of patients followed from January 2018 to December 2019 were analyzed. Thyroid abnormality was assessed through the current history of thyroid disease and laboratory tests - thyrotropin (TSH), free thyroxine (FT4), antithyroid peroxidase (anti-TPO) and antithyroglobulin (anti-TG) antibodies. Patients were classified according to psoriasis severity - Psoriasis Area and Severity Index (PASI), presence of psoriatic arthritis, and current treatment. Subsequently, the results were compared with a control group selected from the literature review.
Of the 250 included patients, 161 were eligible. The prevalence of thyroid abnormality was 28.57% and of hypothyroidism, 14.91%. The mean age was 55 years and the median PASI was 2.2. There was no association between thyroid abnormality and PASI (p=0.8), presence of psoriatic arthritis (p=0.87), or use of immunobiological therapy (p=0.13). The literature control group included 6,227 patients and there was a statistically significant difference for the hypothyroidism variable (p<0.0001).
Absence of a control group from the same center.
This was one of the first Brazilian studies on the prevalence of thyroid abnormality in patients with psoriasis.
银屑病与多种合并症相关，其与甲状腺异常之间存在关联。
评估巴西银屑病患者甲状腺异常的发生率，并分析其与严重程度、存在银屑病关节炎和免疫生物学治疗的相关性。此外，将结果与文献进行比较作为对照。
在这项观察性研究中，分析了 2018 年 1 月至 2019 年 12 月期间接受随访的患者的临床和实验室数据。通过当前的甲状腺疾病病史和实验室检查（促甲状腺激素（TSH）、游离甲状腺素（FT4）、抗甲状腺过氧化物酶（anti-TPO）和抗甲状腺球蛋白（anti-TG）抗体）评估甲状腺异常。根据银屑病严重程度（银屑病面积和严重程度指数（PASI））、存在银屑病关节炎和当前治疗对患者进行分类。随后，将结果与从文献复习中选择的对照组进行比较。
在 250 名纳入的患者中，有 161 名符合条件。甲状腺异常的发生率为 28.57%，其中甲状腺功能减退症的发生率为 14.91%。平均年龄为 55 岁，中位数 PASI 为 2.2。甲状腺异常与 PASI（p=0.8）、银屑病关节炎的存在（p=0.87）或免疫生物学治疗的使用（p=0.13）之间均无相关性。文献对照组纳入了 6227 名患者，其中甲状腺功能减退症变量存在统计学显著差异（p<0.0001）。
缺乏来自同一中心的对照组。
这是巴西首批研究银屑病患者甲状腺异常发生率的研究之一。
